The Red Ferret Journal - 5 new articles

Getting to the toilet is one of the hardest parts of daily life for people who cannot walk or get out of bed — and a Chinese company has now built a robot that solves it by bringing the bathroom to them. Yueban, a Tuobang-owned brand focused on accessible technology, unveiled Xiaoban at the 2026 Shanghai International Aged Care, Assistive Devices, and Rehabilitation Medical Expo. The company is billing it as the world's first self-driving toilet robot.

According to TechEBlog's report on the launch, a user presses a single button on a remote or issues a voice command, and the unit navigates out of its dock, using LiDAR, a 3D obstacle-avoidance AI and multi-sensor fusion to steer around furniture and doorways. Armrests and a backrest aim to reduce the risk of falls.

https://www.youtube.com/watch?v=7pslcbV5250

After use, it handles cleaning itself: a warm-water bidet wash, warm air drying and an ultraviolet light to disinfect, plus an odour-isolation system. It then returns to a docking station plumbed into the house and uses an inbuilt grinder to break down waste and avoid pipe blockages, before self-cleaning, refilling its water tank and recharging. Hope it uses solid state batteries!

Yueban intends Xiaoban for private homes and elder care facilities. In China it is priced at around 28,999 yuan (approximately $4,000); international pricing and availability have not been announced. For some reason the YouTube video says it's $13,000, so your guess is as good as ours as to the real price.

The post Yueban’s Xiaoban Self-Driving Toilet Robot Drives Itself to Your Bedside appeared first on The Red Ferret Journal.

    

Researchers in Germany have erased more than 60 years of molecular aging from human cells in the laboratory, turning blood cells donated by an 80-year-old into stem cells whose biological clocks read as younger than 20. The work, published in the journal Aging Cell, offers scientists a slow-motion window into how cellular age can be wound back.

The team at the University Hospital of Bonn and the University of Bonn, working with RWTH Aachen University, converted immature red blood cell precursors directly into neural stem cells, which can go on to become brain cells. Rather than first pushing the cells back into a pluripotent state, the researchers used a mix of transcription factors to switch identity in a single step. "Using this method, we have directly converted red blood cell precursors into neural stem cells," said Prof. Dr. Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at the University Hospital of Bonn.

The payoff is timing. According to ScienceDaily, the rejuvenation unfolded gradually and was tracked for over 100 days, with roughly 60 years of molecular age gone after about 50 days. Older two-step methods reset the epigenetic clocks almost instantly, leaving little to observe. "Since the epigenetic clocks are slowly reset over several weeks, we can use this model to investigate which factors and active substances accelerate or slow down the rejuvenation process," Brüstle said.

Brüstle stresses the cells "actually behave like young cells," but the finding is a lab model, not an anti-aging therapy: nobody was rejuvenated, and no treatment for aging was discovered. The value lies in studying neurodegenerative disease, since "age is the most important risk factor for neurodegenerative diseases such as Alzheimer's." The work was funded by EU Horizon 2020, the German Research Foundation (DFG) and the Federal Ministry of Research, Technology, and Space.

Photo by Jack B on Unsplash.

The post German Scientists Turn Blood Cells From an 80-Year-Old Into 20 Year Old Stem Cells appeared first on The Red Ferret Journal.

    

Unitree has unveiled a humanoid robot built to guard people rather than fetch their shopping. The Chinese robotics company has unveiled the H2-X Kung Fu Legend Guardian, a 182cm, 70kg machine designed to "serve and protect us". As proof of pedigree the launch showed it leaping off a four-metre platform, kicking its way through a scrapyard and fighting off an intruder.

[embedyt] https://www.youtube.com/watch?v=PzOMT1qJbok[/embedyt]

The H2-X is a sturdier member of Unitree's H2 humanoid line, carrying 31 degrees of freedom and reinforced leg joints for high-impact moves. In a one-minute launch video it front-flips over a car, dents doors with flying kicks, lifts the front end of a vehicle off a trapped dummy, and shields a pedestrian from another car - though the demo rescues used props. Unitree's headline claim is endurance of around eight hours, against roughly three for the standard H2, but an on-screen caption describes that as standing time. We guess intense parkour will reduce battery life a lot!

A great deal remains unknown: the price, the full specifications, and how much of the footage was autonomous, and Unitree's own advice is to stay two to three metres away. The reaction has been part awe, part unease. An r/singularity thread drew more than 500 comments, with one widely shared post joking that the robot "yeeted that kid off the street with more force than the slow moving car would have". The Unitree H2-X robot will definitely be back!

The post Unitree H2-X Kung Fu Legend Guardian is a bodyguard robot that comes with a scary ‘I’ll be back’ vibe appeared first on The Red Ferret Journal.

    

Quick Brief

Featured story today: "Claude reveals ECDSA curve origins" And more models & releases news from the AI universe –

The post AI News – October 17, 2026 appeared first on The Red Ferret Journal.

    

Allegheny County is spending $13.3 million to find out whether the world's best-known weight-loss drug can also treat addiction. Researchers there are planning a clinical trial of semaglutide - sold as Ozempic and Wegovy - in up to 1,200 adults with alcohol and/or opioid use disorder, according to TribLIVE.

The Center for Addiction Science, Policy and Research (CASPR) and the Allegheny County Department of Human Services expect to launch the study in early 2027. Half of the participants will be randomly assigned to receive semaglutide weekly for 52 weeks, alongside - not instead of - traditional care. UPMC Western Psychiatric Hospital's addiction medicine services will be the lead clinical site.

"Research on GLP-1RAs and addiction shows that they can often help restore personal agency," said Nicholas Reville, executive director and co-founder of CASPR. "GLP-1s help quiet that noise for many people."

Unusually for an addiction medication trial, the county will also use administrative data to test whether the drugs improve employment, housing stability, health care use and criminal justice outcomes. "We know that our clients think about recovery in a much more holistic sense," said Alex Jutca, director of the county's Department of Human Services. The four-year trial is funded by Houston-based philanthropy Arnold Ventures.

Photo by Haberdoedas on Unsplash.

The post Using Ozempic To Treat Alcohol and Opioid Addiction appeared first on The Red Ferret Journal.